Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma-Reference-Cited by-同舟云学术

Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma

Published:2012-04-10 Issue:1 Volume:166 Page:177-193
ISSN:0007-1188
Container-title:British Journal of Pharmacology
language:en
Short-container-title:

Author:

May RD,Monk PD,Cohen ES,Manuel D,Dempsey F,Davis NHE,Dodd AJ,Corkill DJ,Woods J,Joberty-Candotti C,Conroy LA,Koentgen F,Martin EC,Wilson R,Brennan N,Powell J,Anderson IK

Publisher

Wiley

Subject

Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1476-5381.2011.01659.x/fullpdf

Reference56 articles.

1. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354);Blanchard;Clin Exp Allergy,2005

2. Isolation of an IL-13-dependent subclone of the B9 cell line useful for the estimation of human IL-13 bioactivity;Bouteiller;J Immunol Methods,1995

3. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys;Bree;J Allergy Clin Immunol,2007

4. Peripheral blood and airway tissue expression of transforming growth factor beta by neutrophils in asthmatic subjects and normal control subjects;Chu;J Allergy Clin Immunol,2000

5. A randomized, controlled, phase 2 study of AMG 317, an IL-4Rα antagonist, in patients with asthma;Corren;Am J Respir Crit Care Med,2010

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Encoding and display technologies for combinatorial libraries in drug discovery: The coming of age from biology to therapy;Acta Pharmaceutica Sinica B;2024-08

2. Interleukin-13 Inhibitors in the Treatment of Atopic Dermatitis: The Role of Tralokinumab;Dermatology Practical & Conceptual;2024-07-31

3. Targeting IL‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years;Allergy;2024-04-02

4. Chemical therapies, immunotherapy, and new treatment strategies for allergic asthma;Allergic Asthma: Immunopathogenesis;2024

5. Engineering the IL‐4/IL‐13 axis for targeted immune modulation;Immunological Reviews;2023-06-07